Medicenna Strengthens Board of Directors with Appointment of Karim Lalji

August 15, 2024

TORONTO and HOUSTON, Aug. 15, 2024 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX:MDNA, OTCQB:MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced today the appointment of Mr. Karim Lalji as a new addition to its Board of Directors effective as of August 14, 2024.

Read more at globenewswire.com

Related news for (MDNAF)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.